InMed Pharmaceuticals Inc (INM) - Total Liabilities
Based on the latest financial reports, InMed Pharmaceuticals Inc (INM) has total liabilities worth $2.24 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
InMed Pharmaceuticals Inc - Total Liabilities Trend (2001–2025)
This chart illustrates how InMed Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of InMed Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
InMed Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of InMed Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AEW UK REIT Plc
LSE:AEWU
|
UK | GBX67.82 Million |
|
ICZOOM Group Inc. Class A Ordinary Shares
NASDAQ:IZM
|
USA | $25.82 Million |
|
Klarsen SA
PA:ALKLA
|
France | €5.91 Million |
|
Sino Hua-An International Bhd
KLSE:2739
|
Malaysia | RM52.87 Million |
|
ELEMENT NUTR.SCIENCES
F:93X
|
Germany | €6.80 Million |
|
Alliance Mining Corp
V:ALM
|
Canada | CA$3.73 Million |
|
Aker Carbon Capture ASA
OL:ACC
|
Norway | Nkr100.00 Million |
|
Foresight Enterprise VCT PLC
LSE:FTF
|
UK | GBX175.00K |
Liability Composition Analysis (2001–2025)
This chart breaks down InMed Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is InMed Pharmaceuticals Inc's balance sheet.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how InMed Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for InMed Pharmaceuticals Inc (2001–2025)
The table below shows the annual total liabilities of InMed Pharmaceuticals Inc from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $2.92 Million | -18.32% |
| 2024-06-30 | $3.58 Million | +33.95% |
| 2023-06-30 | $2.67 Million | -44.06% |
| 2022-06-30 | $4.78 Million | +60.58% |
| 2021-06-30 | $2.97 Million | +54.55% |
| 2020-06-30 | $1.92 Million | +61.64% |
| 2019-06-30 | $1.19 Million | +66.96% |
| 2018-06-30 | $713.02K | +150.85% |
| 2017-06-30 | $284.24K | -37.69% |
| 2016-06-30 | $456.17K | +629.77% |
| 2015-06-30 | $62.51K | -10.84% |
| 2014-06-30 | $70.11K | +42.48% |
| 2013-06-30 | $49.20K | +10.35% |
| 2012-06-30 | $44.59K | -3.49% |
| 2011-06-30 | $46.20K | -96.38% |
| 2010-06-30 | $1.28 Million | +21.19% |
| 2009-06-30 | $1.05 Million | -30.63% |
| 2008-06-30 | $1.52 Million | +12.29% |
| 2007-06-30 | $1.35 Million | +19.05% |
| 2006-06-30 | $1.14 Million | -31.31% |
| 2005-06-30 | $1.66 Million | +111.84% |
| 2004-06-30 | $781.44K | -15.24% |
| 2003-06-30 | $921.99K | +1138.43% |
| 2002-06-30 | $74.45K | -84.90% |
| 2001-06-30 | $493.02K | -- |
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufactur… Read more